cas 1953-04-4|| where to buy Galantamine hydrobromide

Nombre del producto:Galantamine hydrobromide

IUPAC Name:(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol hydrobromide

Unidad de embalaje	Stock disponible	Precio($)
CM110074-100mg	3-4 Weeks	ȖƃŪ
CM110074-250mg	4-5 Weeks	Şȯȯ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1953-04-4 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1953-04-4; Fórmula molecular:C17H22BrNO3; Punto de fusión:-; Código de sonrisas:O(C)C1=C2C=3[C@]4([C@@](O2)(C[C@@H](O)C=C4)[H])CCN(C)CC3C=C1.Br; Densidad:

: Número de catálogo:CM110074; Peso molecular:368.27; Punto de ebullición:; Nº Mdl:MFCD00067672; Almacenamiento:Store at 2-8 ℃

: ZUNVEYL; Alpha Cognition announced that the FDA has granted approval for ZUNVEYL® (benzgalantamine) previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer’s disease. ZUNVEYL, a prodrug of AD treatment galantamine and an acetylcholinesterase inhibitor (AChEI), is postulated to exert its therapeutic effect by preventing the breakdown of acetylcholine, the important brain neurotransmitter involved in memory, motivation, and attention functions. The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer’s disease as it is only the second oral AD treatment to be approved in more than a decade.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.